Arca
Skip to content
Tools
Tools

Cutaneous melanoma

Drug research and approvals for cutaneous melanoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 478 studies of cutaneous melanoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 478
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 478 recruiting on ClinicalTrials.gov ↗

How its trials ended

221 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 59 whose ending is known, 36% met their primary endpoint, 5% missed it and 59% stopped early.

  • Ongoing9945%
  • Completed, result not reported5625%
  • Met its primary endpoint2110%
  • Stopped: other or unclear188%
  • Stopped: enrollment or feasibility105%
  • Status unknown73%
  • Missed its primary endpoint31%
  • Stopped: sponsor or business decision31%
  • Stopped: funding31%
  • Stopped: lack of efficacy1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 14, 2025Suprame - actengine IMA203 vs. investigator's choice of treatment in previously treated, unresectable or metastatic cutaneous melanomaIMA203 / ProleukinImmatics US, Inc.Ongoing
Jul 29, 2024A randomized, open-label phase 3 study in patients with previously treated unresectable or metastatic nras mutant cutaneous melanoma comparing the combination…Naporafenib (LXH254, ERAS-254)/ Trametinib (TMT212)ErascaClosed
Jul 5, 2023A phase 1 study of INCB099280 in combination with ipilimumab in participants with select solid tumorsINCB099280 / IpilimumabIncyteClosed
May 20, 2020The response to intralesional IL-2 and/or bcg treatment for cutaneous metastatic melanomaProleukin (aldesleukin) / Oncotice (bacillus calmete guerin, strain tice) /…Nova Scotia Health AuthorityPending
Jul 2, 2014Adjuvant pegylated-interferon-ALPHA2B (sylatrontm) for two years vs observation in patients with an ulcerated primary cutaneous melanoma t (2-4)BN0M0: a…Peginterferon ALFA-2BNcic Clinical Trials Group Queens UniversityPending

FDA orphan designations

Approved first, then open designations, newest first
Oct 28, 2015YervoyFor the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who…Bristol-Myers Squibb CompanyApproved
Feb 3, 2026An adoptive cellular therapy (ACT) based on the use of…Treatment of Stage II and higher cutaneous melanoma (CM), in human leukocyte antigen (HLA)-A*02:01-positive patientsImmatics US, IncDesignated
Nov 12, 2008Melphalan hydrochlorideTreatment of patients with cutaneous melanoma.Delcath Systems, Inc.Designated
Sep 19, 1994Monoclonal Ab(murine) anti-idiotype melanoma-associated…Treatment of invasive cutaneous melanoma.IDEC Pharmaceuticals CorporationDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.